AbbVie presented 60 abstracts at the 2026 European Academy of Dermatology and Venereology Congress, showcasing new data on its dermatology portfolio including approved drugs risankizumab (SKYRIZI) and upadacitinib (RINVOQ), as well as investigational compounds lutikizumab and zumilokibart. The data covers a range of immune-mediated skin diseases such as alopecia areata, atopic dermatitis, hidradenitis suppurativa, vitiligo, psoriasis, and psoriatic arthritis, highlighting efficacy and safety across diverse patient groups. This research underlines AbbVie's commitment to advancing treatments and improving patient outcomes in dermatology. Further clinical trial results and real-world evidence will continue to inform future therapeutic strategies.
AbbVie shares trade at USD 264.00 on Pluang as of Sep 30, 2026 12:12 WIB, down 0.90% in the last day. The stock shows strong investor interest with 74% buy orders and a market cap of $470.55 billion. AbbVie's dividend yield stands at 2.6%, reflecting steady income potential amid its ongoing dermatology research advancements.
AbbVie announced positive Phase 2 results for zumilokibart, a monoclonal antibody targeting IL-13, in adults with moderate-to-severe atopic dermatitis. All dose regimens met the primary endpoint with significant improvements in skin severity and itch...
AbbVie has formed a new collaboration with Valkai to enhance its artificial intelligence (AI) capabilities in clinical development. This partnership aims to improve efficiency in clinical research, accelerate insight generation, and reduce drug devel...
AbbVie announced FDA approval of JUVMO™ (tavapadon), the first selective D1/D5 receptor agonist for treating adults with Parkinson's disease. JUVMO offers a novel approach to motor symptom control, improving daily functioning and increasing 'on' time...
AbbVie and Johnson & Johnson are both strong dividend stocks trading near their 52-week highs, but they differ significantly in risk and growth. AbbVie shows faster revenue growth and a higher dividend yield, driven by its immunology drugs, but faces...
